Update on quadrivalent human papillomavirus vaccination and pregnancy outcomes: Is contraception advisable?

Obstetrics and Gynecology

Volumn 114, Issue 6, 2009, Pages 1168-1169

  Smith McCune, Karen ^a   Sawaya, George F ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE; HUMAN PAPILLOMAVIRUS VACCINE L1, TYPE 6,11,16,18;

ADVERSE OUTCOME; ANENCEPHALUS; DRUG TOLERABILITY; FEMALE; FETUS DEATH; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 6; POSTMARKETING SURVEILLANCE; PREGNANCY OUTCOME; PRIORITY JOURNAL; REGISTER; SCHIZENCEPHALY; SHORT SURVEY; SPONTANEOUS ABORTION; VACCINATION; CHEMICALLY INDUCED DISORDER; CONTRACEPTION; NOTE; PREGNANCY; PREGNANCY COMPLICATION;

CONTRACEPTION; FEMALE; HUMANS; PAPILLOMAVIRUS VACCINES; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY OUTCOME;

EID: 73349105628     PISSN: 00297844     EISSN: None     Source Type: Journal    
DOI: 10.1097/AOG.0b013e3181c479f8     Document Type: Short Survey

References (3)

1. Dana A, Buchanan KM, Gos MA, Seminack MM, Shields KE, Korn S, et al. Pregnancy outcomes from the Pregnancy Registry of the quadrivalent human papillomavirus types 6/11/ 16/18 vaccine. Obstet Gynecol 2009;114:1170-1178
2. Garland SM, Ault KA, Gall SA, Paavonen J, Sings HL, Ciprero KL, et al. Pregnancy outcomes in the clinical trials of the human papillomavirus type 6/11/16/18 vaccine. Obstet Gynecol 2009;114:1179-1188
3. The FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007;356:1915-1927